Using advanced imaging techniques to assess treatment response after liver therapy
Deuterium Metabolic MRI and [18F]-Flourodesoxyglucose Positron Emission Tomography for Assessment of Treatment Response Following Radioembolization; Pilot Study
This study is testing new imaging methods to see how well liver cancer treatment works in patients with liver metastases after they receive Selective Internal Radiation Therapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | UMC Utrecht Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Utrecht) |
| Trial ID | NCT06232889 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Deuterium Metabolic MRI and [18F]FDG PET imaging in assessing treatment response in patients undergoing Selective Internal Radiation Therapy (SIRT) for liver metastases. It aims to determine the optimal timing for restaging after treatment and improve the accuracy of imaging in detecting small metastases. The study focuses on patients with liver-only or liver-dominant disease who are eligible for SIRT and have measurable liver metastases. By utilizing advanced imaging techniques, the study seeks to enhance the assessment of treatment response compared to conventional imaging methods.
Who should consider this trial
Good fit: Ideal candidates are adults with liver-only or liver-dominant metastatic disease who are eligible for SIRT and have measurable liver metastases.
Not a fit: Patients with FDG-negative disease, diabetes mellitus, or contraindications for SIRT or MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate assessments of treatment response, improving patient management and outcomes.
How similar studies have performed: While the use of advanced imaging techniques is promising, the specific combination of Deuterium Metabolic MRI and [18F]FDG PET for this purpose is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years) * Referred for SIRT and deemed eligible by the multidisciplinary tumor board * Size of at least one liver metastasis ≥ 1 cm on contrast enhanced CT / MRI (measurable according to RECIST 1.1) and 18FDG-avid metastatic liver disease (uptake \> healthy liver uptake; measurable according to PERCIST) * Written informed consent Exclusion Criteria: * Patients having FDG-negative disease (according to PERCIST) * Patients with diabetes mellitus * Patients having a general contra-indication for SIRT * Patients with contra-indications for 7T MR scanning * Patient unable to complete study scan (laying still for a long time) * Patient unable or incapable to follow study proceedings
Where this trial is running
Utrecht
- UMC Utrecht — Utrecht, Netherlands (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.